AIM
ARLZ

Advantage Investment Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Advantage Investment Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-68
Closed – – 1052
2016
Q3 		$0 Hold
68
– – ﹤0.01% 1008
2016
Q2 		$0 Buy
+68
New +$257 ﹤0.01% 978

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advantage Investment Management's ARLZ Position: Q4 2016 in Review

Advantage Investment Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q4 2016, closing a stake of 68 shares.

Advantage Investment Management first reported a position in ARLZ in Q2 2016 and held it in 2 quarters. The position peaked at $0 in Q3 2016. 83 funds tracked by Wall St. Rank hold ARLZ as of Q4 2016.

  • Advantage Investment Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
  • Advantage Investment Management sold 68 Aralez Pharmaceuticals Inc. shares in Q4 2016.
  • Advantage Investment Management first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 2 quarters.
  • Advantage Investment Management's Aralez Pharmaceuticals Inc. position peaked at $0 in Q3 2016.
  • 83 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q4 2016.

Based on Advantage Investment Management's 13F filing for Q4 2016, filed 17 Feb 2017.